List of Sponsors

Personalizing cancer care demands the right tools to get patients the right treatment at theright time. Our integrated value chain of precision oncology tools equips theranostics programs with state-of-the-art solutions at every step of the theranostics care pathway. Visit us at Booth #D10 to learn more about how Siemens Healthineers is empowering precision oncology.

ITM is dedicated to providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and partners through excellence in development, production and global supply. ITM is advancing a broad pipeline to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne, AllinOne mini, AllinOne S and EasyOne), Quality Control instrument (QC1) dose preparation equipment (Unidose), their shielding and accessories. We also develop customized synthetic methods and instruments. As certified GMP part I and Part II, we can provide GMP Active Pharmaceutical Ingredients (API) and support our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

Perspective Therapeutics is a clinical stage precision medicine company with a broad pipeline, and two prioritized lead programs in clinic. We are developing a new class of image guided alpha-particle treatments, with an initial focus on neuroendocrine tumors (NETs) and metastatic melanoma, and a robust discovery platform advancing our pipeline into the clinic. Perspective’s personalized theranostic approach captures information about a patient’s cancer which is used to guide precise radiation therapy, killing cancers from the inside out. Alpha-particles generate more energy and travel a shorter distance compared to beta-particles, making them more cytotoxic, while reducing their effects on healthy tissue.

Choose excellence for your radiopharma production – IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. Headquartered in Belgium, IBA installed and supports over 320 cyclotrons and more than 750 Synthera® synthesizers across the world. Based on almost 40 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, urology, neuroimaging, and cardiac imaging. Combined with MIM’s quick and easy AI-powered total tumor burden calculation, MIM SurePlan MRT and LiverY90 provide timesaving tools for organ and tumor segmentation, registration, and post-treatment voxel-based dosimetry.

Tecnonuclear is a prominent Argentine company in the field of Nuclear Medicine, With a history spanning over 30 years within the Argentine market. In 2022, Tecnonuclear became a part of the Eckert & Ziegler group. Founded in Berlin in 1992 by Dr. Andreas Eckert and Jürgen Ziegler, Eckert & Ziegler is one of the world’s leading suppliers of isotopic technology for medical, scientific, and industrial applications.

TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative and novel radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in cancer healthcare and provides the first commercial product of its kind. Produced at the highest radiochemical grade, and soon available as GMP product, this carrier-free lanthanide (NCA) holds promise for Radioligand Therapy. Early research suggests Tb-161 can improve the anti-tumor capabilities, especially for (micro)metastasized cancers, due to the highest addition of Auger and conversion electrons when compared to other known radiolanthanides.

Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials and demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 70 countries around the globe.

TrisKem International develops, manufactures and commercializes selective resins for the separation and quality control of radionuclides such as nca Lu-177, nca Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, alpha emitters (e.g. Ac-225, Pb-212,…), Ge-68, Ti-44/5, Sc-43/4/7 and many other radionuclides for medical purposes. TrisKem also provides selective chromatography paper (DGA Sheets, CU Sheets, more under development) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68, Cu-61/4/7,…). Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs.

Contact us at contact@triskem.fr for more information.

CPO is a private Foundation active in scaling global patient access to Radiomolecular Precision Oncology thanks to shared knowledge, standards and education through the establishment of an international collaborative network of ICPO certified centers. The International Centers for Precision Oncology Foundation (ICPO) was established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift.

The ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a social franchise model based on shared know-how, certified education as well as design and process standardization that enables best clinical practice globally. For this purpose, the ICPO Academy for Theranostics was launched 2023. Furthermore, it is the ICPO Foundation’s objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status.

Learn more about the ICPO Foundation at www.icpo.foundation and about the ICPO Academy for theranostics at www.theranostics.academy

Tema Sinergie is one of the leading companies worldwide providing a complete range of products and services for all professionals and institutions working with ionizing radiation. From synthesis and dispensing hot cells, to dose drawing systems, radiopharmaceutical injectors, monitoring systems and much more, Tema Sinergie is the ideal partner for every application within Nuclear Medicine.

ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation. Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials.

Isotopia is a leader in diagnostic and therapeutic radioactive solutions. We produce and supply Lutetium (177Lu), both no-carrier-added (NCA) and carrier-added (CA), particularly for metastatic prostate cancer and neuroendocrine tumors. With consistent and sustainable supply, we have expanded globally with cutting-edge production facilities y, in North America and Europe. Isotopia is a well-established platform for managing the entire process from manufacturing through to delivery. Our dedicated professional teams provide round-the-clock customer services, regulatory guidance, and support. We are excited about our global expansion, PSMA radiolabelling kit, Lutetium (177Lu) European marketing authorization, and distribution reinforcing our commitment to advancing personalized cancer care through Theranostics.

ROTOP has an extensive expertise in the field of product development and product application as well as commercial cGMP production including distribution. At our facility, we combine the complete know-how from pharmaceutical development including regulatory affairs, cGMP manufacturing of APIs and sterile drug products as well as an independent Q-unit with several Qualified Persons (QP) to release drug products.

For more information about our products and CDMO services visit: www.rotop-pharmaka.com.

RQS (Ruffani Quality Solutions) was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation. A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application.

In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast. The team of now 10 employees worldwide is ready to support you with all your requests and is looking forward to get in contact with you.

SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine.

For more information, please visit https://sofie.com or contact info@sofie.com

Yantai Lannacheng Biotechnology Co., Ltd., (LNC) was founded in 2021. As a wholly owned subsidiary of Yantai Dongcheng Pharmaceutical Group (Dongcheng), LNC is dedicated to develop and commercialize first-in-class radioligand theranostics, and is committed to becoming a global leader in radiopharmaceutical innovation. LNC has established its comprehensive industry chain covering early development, radiolabeling, and clinical studies.

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.

TeamBest®, through Best Cyclotron Systems (BCS), offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. BCS’s mission is to create technology to provide healthcare options for various needs around the world. Our staff assists from the planning stage, detailed design, facility construction, daily production, maintenance and emergency repair through the TeamBest®network. We provide solutions for PET-CT and molecular imaging radiopharmaceuticals with the same excellent customized care as demonstrated in our 40+ year history of radiotherapy support.

SHINE Technologies has the largest n.c.a. lutetium-177 production facility in North America. We offer a secure, stable supply of isotopes, and plan to become the first vertically integrated supplier of Lu-177 in the world.

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes. We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture or source nca Lu-177 and other radioisotopes of interest. We are dedicated to improving the accessibility and supply security of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.

benfovir AG is a clinical stage company developing drugs for the treatment of viral diseases and cancers. benfovir’s drug candidate inhibits sugar and lipid metabolism, thereby preventing the generation of the crucial building blocks for cell proliferation and DNA repair, leading to a sensitization of tumors towards radiotherapy.

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

PanTera, an IBA and SCK CEN joint-venture, aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, PanTera’s ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general.

More information can be found at: www.pantera-life.com

The U.S. Department of Energy Isotope Program supports the production, as well as the development of production techniques, of radioactive and stable isotopes that are in short supply. Isotopes are high-priority commodities of strategic importance for the Nation and are essential for energy, medical, and national security applications and for basic research. A goal of the program is to make critical isotopes more readily available to meet domestic needs.

The National Isotope Development Center (NIDC) is funded by the U.S. Department of Energy Isotope Program (DOE IP). It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

Technologies develops a tetrazine-based click chemistry platform to radiolabel any type of targeting vector. We focus on radiohalogens, including astatine-211 and iodine-131, making it as easy to label with these as it is with radiometals. The TetraKit platform enables rapid and versatile, plug-n-play lead optimization and practical and attractive modular radiosynthesis. We have demonstrated the platform on PSMA, octreotate, FAPi, and others. We are developing a proprietary lead program based on FAPi dimers, which are highly promising and show extended tumor residence, thereby enabling effective FAP-targeted therapy. We look for platform-based research collaborations, drug development partnerships, and investment.

Alpha Nuclide is a radiopharmaceutical company focusing on the supply of astatine-211, providing research and development services as well as manufacturing services of radiopharmaceuticals, and development of targeted alpha-particle therapy agents in China. Alpha Nuclide is located in Zhejiang Province just outside of Shanghai, and equipped with two 30 MeV cyclotrons one of which is dedicated to At-211 production. Together with a full R&D radiopharmaceutical lab and a cGMP facility, Alpha Nuclide aim to provide R&D and clinical support in China and international partners.

IONETIX Alpha is a US-based cyclotron and technology company providing full-service, alpha-emitting radioisotope production and end-to-end radiopharmaceutical, development and manufacturing services. Utilizing a proprietary cyclotron technology platform, Ionetix Alpha has developed innovative cyclotron accelerator solutions for, high-yield production of alpha-emitting radioisotopes used in therapeutic, radiopharmaceuticals. This includes high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211), alpha-emitting radioisotopes. Production and distribution of GMP grade, supply of these radioisotopes will begin in the second half of 2024.

Toshiba group has four business cores, energy, social infrastructure, electronic devices, and digital solutions. We are a leading supplier of integrated energy solutions. With our long experience and expertise in a wide range of nuclear power equipment and plants and advanced technologies which are based on R&D for fusion, accelerator and so on – we contribute to new solutions in the field of healthcare. We are promoting to realize the next-generation healthcare services with advanced IoT and AI technologies utilizing our knowledge and know-how we have accumulated in energy system development and manufacturing.

Since its establishment, Sumitomo Heavy Industries, Ltd. has contributed to the society by providing advanced technologies related to industrial machinery and infrastructure equipment to customers in the world. In particular, we have accumulated over 50 years of experience in the manufacture of accelerators, which have been applied to scientific, industrial and medical fields and have earned a high reputation.

In the nuclear medicine, Sumitomo PET radio-tracer production system (incl. cyclotron, target, synthesizer, etc.) were delivered to more than 220 sites in the world and have been contributed for the development of clinical use and new technologies (such as Theranostics).

Atley Solutions is the world-leader in commercial production equipment for radiopharmaceuticals based on the promising alpha-emitter astatine-211. Atley’s first hardware product, the Atley C100, allows for automated purification of At-211 from cyclotron targets, as well as automated radiolabeling compatible with a wide range of targeting molecules and labeling methods. Atley also provides non-clinical radiopharmaceutical development services which include access to At-211.